RT Journal Article
T1 Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics
A1 Fernandez-Peralbo, M. A.
A1 Gomez-Gomez, E.
A1 Calderon-Santiago, M.
A1 Carrasco-Valiente, J.
A1 Ruiz-Garcia, J.
A1 Requena-Tapia, M. J.
A1 Luque de Castro, M. D.
A1 Priego-Capote, F.
K1 Dna demethylation
K1 Methylation
K1 5-hydroxymethylcytosine
K1 5-methylcytosine
K1 Identification
K1 Progression
K1 Biomarkers
K1 Conversion
K1 Sarcosine
AB The existing clinical biomarkers for prostate cancer (PCa) diagnosis are far from ideal (e.g., the prostate specific antigen (PSA) serum level suffers from lack of specificity, providing frequent false positives leading to over-diagnosis). A key step in the search for minimum invasive tests to complement or replace PSA should be supported on the changes experienced by the biochemical pathways in PCa patients as compared to negative biopsy control individuals. In this research a comprehensive global analysis by LC-QTOF was applied to urine from 62 patients with a clinically significant PCa and 42 healthy individuals, both groups confirmed by biopsy. An unpaired t-test (p-value<0.05) provided 28 significant metabolites tentatively identified in urine, used to develop a partial least squares discriminant analysis (PLS-DA) model characterized by 88.4 and 92.9% of sensitivity and specificity, respectively. Among the 28 significant metabolites 27 were present at lower concentrations in PCa patients than in control individuals, while only one reported higher concentrations in PCa patients. The connection among the biochemical pathways in which they are involved (DNA methylation, epigenetic marks on histones and RNA cap methylation) could explain the concentration changes with PCa and supports, once again, the role of metabolomics in upstream processes.
PB Nature Publishing Group
SN 2045-2322
YR 2016
FD 2016-12-04
LK http://hdl.handle.net/10668/18914
UL http://hdl.handle.net/10668/18914
LA en
NO Fernández-Peralbo MA, Gómez-Gómez E, Calderón-Santiago M, Carrasco-Valiente J, Ruiz-García J, Requena-Tapia MJ, et al. Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics. Sci Rep. 2016 Dec 2;6:38243
NO The Spanish Ministerio de Economía y Competitividad (MINECO), Junta de Andalucía and FEDER programme  are gratefully acknowledged for financial support (Projects “Development of methods for early cancer detection”, FQM-1602 and CTQ2015-68813-R). M. A. Fernández-Peralbo and M. Calderón-Santiago also thank to these organisms their research contracts. The biological samples repository of Reina Sofía Hospital (Córdoba, Spain) is also gratefully acknowledged for coordination tasks in the selection of urine samples
DS RISalud
RD Apr 7, 2025